

APPENDIX 3 - Description of relevant studies - Cell-based therapies for COVID-19: A living systematic review

INCLUDED STUDIES

No studies were found

EXCLUDED STUDIES

Study name	Reason for exclusion
Liang et al	Not a comparative study (case report)
Leng et al	Not a comparative study (case series)

References to excluded studies

1. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Nie P, Gao Y. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. chinaXiv. 2020; [Epistemonikos](#)
2. Leng et al, Zikuan, Zhu, Rongjia, Hou, Wei, Feng, Yingmei, Yang, Yanlei, Han, Qin, Shan, Guangliang, Meng, Fanyan, Du, Dongshu, Wang, Shihua. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and disease. 2020;11(2):216-228. [Epistemonikos](#)

ONGOING STUDIES

References to ongoing randomised trials

1. Puren Hospital Affiliated to Wuhan University of Science and Technology. Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia. clinicaltrials.gov. 2020;
2. Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020
3. Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
4. Cancelled by the investigator Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020
5. Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial. Chinese Clinical Trial Registry. 2020;
6. Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial. Chinese Clinical Trial Registry. 2020;
7. Tianhe Stem Cell Biotechnologies Inc.. Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2. clinicaltrials.gov. 2020;
8. Feng Ganzhu. Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
9. Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
10. Guangzhou Institute of Respiratory Disease. Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19). clinicaltrials.gov. 2020;
11. Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trial. Chinese Clinical Trial Registry. 2020;
12. Rigshospitalet, Denmark. ASC Therapy for Patients With Severe Respiratory COVID-19. clinicaltrials.gov. 2020;
13. Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
14. Beijing 302 Hospital. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19). clinicaltrials.gov. 2020;
15. Renmin Hospital of Wuhan University. Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients. clinicaltrials.gov. 2020;
16. Chongqing Public Health Medical Center. A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19. clinicaltrials.gov. 2020;

17. Hope Biosciences. A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19. clinicaltrials.gov. 2020;
18. Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration. Chinese Clinical Trial Registry. 2020;
19. Assistance Publique - Hôpitaux de Paris. Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS. clinicaltrials.gov. 2020;
20. Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. BAttLe Against COVID-19 Using Mesenchymal Stromal Cells. clinicaltrials.gov. 2020;
21. Belfast Health and Social Care Trust. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)(COVID-19). clinicaltrials.gov. 2019;
22. Camillo Ricordi. Use of UC-MSCs for COVID-19 Patients. clinicaltrials.gov. 2020;
23. Cancelled by the investigator Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
24. Xinxiang medical university. NK Cells Treatment for Novel Coronavirus Pneumonia. clinicaltrials.gov. 2020;
25. Puren Hospital Affiliated to Wuhan University of Science and Technology. Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus. clinicaltrials.gov. 2020;
26. Cancelled by the investigator Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
27. Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
28. Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
29. Evaluation of the efficacy and safety of cord-derived mesenchymal stem cell transplantation in the treatment of COVID-19. Iranian Registry of Clinical Trials. 2020;
30. Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial. Iranian Registry of Clinical Trials. 2020;
31. Histocell S.L.. Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19). EU Clinical Trials Register. 2020;
32. Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19. EU Clinical Trials Register. 2020;
33. CITOSPIN S.L.. Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV[®]-allo) in acute respiratory failure in patients with COVID-19 pneumonia. EU Clinical Trials Register. 2020;

34. Cancelled by the investigator Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
35. Cancelled by the investigator Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
36. Qingsong Ye, Chenliang Zhou, . Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients. Chinese Clinical Trial Registry. 2020;
37. Wuhan Union Hospital, China. Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia. clinicaltrials.gov. 2020;
38. HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
39. Lanjuan Li, Xiaowei Xu, Charile Xiang. Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;

References to other ongoing studies (not randomised)

1. Zhao RC. Stem cell-based therapy for coronavirus disease 2019. Stem cells and development. 2020;
2. Ruijin Hospital. A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia. clinicaltrials.gov. 2020;
3. The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
4. Azidus Brasil. NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia. clinicaltrials.gov. 2020;
5. Fu-Sheng Wang. Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis. Chinese Clinical Trial Registry. 2020;
6. Hope Biosciences. A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19. clinicaltrials.gov. 2020;
7. Beijing 302 Hospital. Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus. clinicaltrials.gov. 2020;
8. Cancelled by the investigator Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients. Chinese Clinical Trial Registry. 2020;
9. Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
10. Baylor College of Medicine. Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease). clinicaltrials.gov. 2020;

11. Stem Cells Arabia. Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells. clinicaltrials.gov. 2020;
12. Universidad Nacional de Colombia. Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia. clinicaltrials.gov. 2020;
13. Dou Qifeng. Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
14. Mesenchymal stem cell utilization in reducing complications and enhancing pneumonia healing in patients infected with 2019-nCoV (phase I clinical trial). Iranian Registry of Clinical Trials. 2020;
15. Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection : A Phase 1 and 2 clinical trial. Iranian Registry of Clinical Trials. 2020;
16. Study the effect of intravenous injection of dental pulp mesenchymal stem cells in treatment of patients with COVID-19 pneumonia. Iranian Registry of Clinical Trials. 2020;
17. Cell therapy in patients with coronavirus19 using mesenchymal stem cells. Iranian Registry of Clinical Trials. 2020;
18. ZhiYong Peng. Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia. clinicaltrials.gov. 2020;
19. CAR-T (Shanghai) Biotechnology Co., Ltd.. Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells. clinicaltrials.gov. 2020;
20. Zhang Dingyu. Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19). Chinese Clinical Trial Registry. 2020;
21. Regeneris Medical. Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease. clinicaltrials.gov. 2020;
22. Chinese Academy of Sciences. Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS. clinicaltrials.gov. 2020;